SG10201608528YA - Hepatitis b antiviral agents - Google Patents

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/54—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C211/44—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring
- C07C211/45—Monoamines
- C07C211/46—Aniline
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C211/44—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring
- C07C211/45—Monoamines
- C07C211/48—N-alkylated amines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C211/44—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring
- C07C211/49—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring having at least two amino groups bound to the carbon skeleton
- C07C211/50—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring having at least two amino groups bound to the carbon skeleton with at least two amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
- C07C303/38—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reaction of ammonia or amines with sulfonic acids, or with esters, anhydrides, or halides thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/17—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/46—Y being a hydrogen or a carbon atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/42—Oxygen atoms attached in position 3 or 5
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
- C07D211/50—Aroyl radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
- C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/195—Radicals derived from nitrogen analogues of carboxylic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/22—Nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Zoology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biotechnology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Hydrogenated Pyridines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pyrrole Compounds (AREA)
Pyridine Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Furan Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

SG10201608528YA2011-12-212012-12-21Hepatitis b antiviral agentsSG10201608528YA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161578716P	2011-12-21	2011-12-21
US201261709331P	2012-10-03	2012-10-03

Publications (1)

Publication Number	Publication Date
SG10201608528YAtrue SG10201608528YA (en)	2016-12-29

Family

ID=48669530

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG11201402660YASG11201402660YA (en)	2011-12-21	2012-12-21	Hepatitis b antiviral agents
SG10201608528YASG10201608528YA (en)	2011-12-21	2012-12-21	Hepatitis b antiviral agents

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SG11201402660YASG11201402660YA (en)	2011-12-21	2012-12-21	Hepatitis b antiviral agents

Country Status (21)

Country	Link
US (6)	US8629274B2 (en)
EP (2)	EP2794565B1 (en)
JP (3)	JP5977837B2 (en)
KR (3)	KR20190007106A (en)
CN (2)	CN104144913B (en)
AR (1)	AR090044A1 (en)
AU (3)	AU2012358332C1 (en)
BR (1)	BR112014015197A2 (en)
CA (1)	CA2857344C (en)
CL (1)	CL2014001463A1 (en)
CO (1)	CO7051027A2 (en)
DK (1)	DK2794565T3 (en)
EA (2)	EA026368B1 (en)
ES (2)	ES2797123T3 (en)
HK (1)	HK1254462A1 (en)
IL (1)	IL233182A0 (en)
MX (1)	MX359634B (en)
PH (1)	PH12014501314A1 (en)
SG (2)	SG11201402660YA (en)
TW (3)	TWI622578B (en)
WO (1)	WO2013096744A1 (en)

Families Citing this family (251)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2726459B1 (en)*	2011-07-01	2019-09-11	Baruch S. Blumberg Institute	Sulfamoylbenzamide derivatives as antiviral agents against hbv infection
TWI622578B (en)	2011-12-21	2018-05-01	諾維拉治療公司	Hepatitis b antiviral agents
UA123256C2 (en)*	2012-08-28	2021-03-10	ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі	SULFAMOYLARYLAMIDES AND THEIR USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
MY174042A (en)	2012-08-28	2020-03-05	Janssen Sciences Ireland Uc	Fused bicyclic sulfamoyl derivative and the use thereof as medicaments for the treatment of hepatitis b.
US9938236B2 (en)	2012-12-27	2018-04-10	Drexel University	Antiviral agents against HBV infection
PT2961732T (en)	2013-02-28	2017-06-26	Janssen Sciences Ireland Uc	Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
WO2014165128A2 (en)	2013-03-12	2014-10-09	Novira Therapeutics, Inc.	Hepatitis b antiviral agents
DK2981536T3 (en)	2013-04-03	2017-09-25	Janssen Sciences Ireland Uc	N-PHENYLC CARBOXAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
CA2909742C (en)	2013-05-17	2020-08-04	Janssen Sciences Ireland Uc	Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
JO3603B1 (en)	2013-05-17	2020-07-05	Janssen Sciences Ireland Uc	Sulfamoyl pyrolamide derivatives and their use as medicines to treat hepatitis B
DK3024819T3 (en)*	2013-07-25	2018-06-06	Janssen Sciences Ireland Uc	GLYOXAMIDE-SUBSTITUTED PYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B
AU2014338947B2 (en)*	2013-10-23	2018-02-22	Janssen Sciences Ireland Uc	Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
EA201690979A1 (en)	2013-11-14	2016-08-31	Новира Терапьютикс, Инк.	AZEPAN DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS
US9181288B2 (en)	2014-01-16	2015-11-10	Novira Therapeutics, Inc.	Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en)	2014-01-16	2019-08-27	Novira Therapeutics, Inc.	Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en)	2014-01-16	2015-10-27	Novira Therapeutics, Inc.	Azepane derivatives and methods of treating hepatitis B infections
KR20160128305A (en)*	2014-02-05	2016-11-07	노비라 테라퓨틱스, 인코포레이티드	Combination therapy for treatment of hbv infections
CN110483484A (en)*	2014-02-06	2019-11-22	爱尔兰詹森科学公司	Sulfamoyl pyrrole amides derivative and its purposes for being used to treat hepatitis B as drug
US9400280B2 (en)	2014-03-27	2016-07-26	Novira Therapeutics, Inc.	Piperidine derivatives and methods of treating hepatitis B infections
EP3139954A4 (en)*	2014-05-09	2018-02-28	Indiana University Research and Technology Corporation	Methods and compositions for treating hepatitis b virus infections
PL3154989T3 (en)	2014-06-11	2021-10-18	VenatoRx Pharmaceuticals, Inc.	Beta-lactamase inhibitors
TWI677489B (en)	2014-06-20	2019-11-21	美商基利科學股份有限公司	Synthesis of polycyclic-carbamoylpyridone compounds
CN107406378A (en)*	2014-12-02	2017-11-28	诺维拉治疗公司	Sulfated alkyl compounds and pyridine trans-sulfonamide compounds for HBV treatment
US9597332B2 (en)	2014-12-02	2017-03-21	Novira Therapeutics, Inc.	Sulfide alkyl compounds for HBV treatment
CN110372559A (en)*	2014-12-29	2019-10-25	重庆博腾制药科技股份有限公司	One kind (4S)-N-Boc-4-- methoxy-L-PROLINE synthetic method
US9765050B2 (en)	2014-12-30	2017-09-19	Novira Therapeutics, Inc.	Pyridyl reverse sulfonamides for HBV treatment
MA41338B1 (en)	2015-01-16	2019-07-31	Hoffmann La Roche	Pyrazine compounds for the treatment of infectious diseases
MD3097102T2 (en)	2015-03-04	2018-02-28	Gilead Sciences Inc	Toll-like receptor modulating 4,6-diamino-pyrido[3,2-D]pyrimidine compounds
EP3845227A1 (en)*	2015-03-16	2021-07-07	F. Hoffmann-La Roche AG	Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
HK1247147A1 (en)*	2015-03-19	2018-09-21	诺维拉治疗公司	Azocane and azonane derivatives and methods of treating hepatitis b infections
WO2016161268A1 (en)*	2015-04-01	2016-10-06	Enanta Pharmaceuticals, Inc.	Hepatitis b antviral agents
US10738035B2 (en)	2015-05-13	2020-08-11	Enanta Pharmaceuticals, Inc.	Hepatitis B antiviral agents
US10875876B2 (en)	2015-07-02	2020-12-29	Janssen Sciences Ireland Uc	Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10179131B2 (en)	2015-07-13	2019-01-15	Enanta Pharmaceuticals, Inc.	Hepatitis B antiviral agents
US10301255B2 (en)	2015-07-22	2019-05-28	Enanta Pharmaceuticals, Inc.	Hepatitis B antiviral agents
AU2016312508A1 (en)	2015-08-26	2018-02-15	Gilead Sciences, Inc.	Deuterated toll-like receptor modulators
HK1259410A1 (en)*	2015-09-29	2019-11-29	诺维拉治疗公司	Crystalline forms of a hepatitis b antiviral agent
WO2017106346A2 (en)	2015-12-15	2017-06-22	Gilead Sciences, Inc.	Human immunodeficiency virus neutralizing antibodies
US10280175B2 (en)	2016-02-02	2019-05-07	Enanta Pharmaceuticals, Inc.	Hepatitis B antiviral agents
BR112018016842A2 (en)	2016-02-19	2018-12-26	Novartis Ag	tetracyclic pyridone compounds as antivirals
MX384836B (en)*	2016-03-07	2025-03-14	Enanta Pharm Inc	ANTIVIRAL AGENTS AGAINST HEPATITIS B
WO2017156255A1 (en)	2016-03-09	2017-09-14	Emory University	Elimination of hepatitis b virus with antiviral agents
SG10202011827YA (en)*	2016-04-15	2021-01-28	Novira Therapeutics Inc	Combinations and methods comprising a capsid assembly inhibitor
WO2017197051A1 (en)	2016-05-10	2017-11-16	C4 Therapeutics, Inc.	Amine-linked c3-glutarimide degronimers for target protein degradation
ES2990061T3 (en)	2016-05-10	2024-11-28	C4 Therapeutics Inc	Spirocyclic degronimers for the degradation of target proteins
WO2017197046A1 (en)	2016-05-10	2017-11-16	C4 Therapeutics, Inc.	C3-carbon linked glutarimide degronimers for target protein degradation
WO2017197055A1 (en)	2016-05-10	2017-11-16	C4 Therapeutics, Inc.	Heterocyclic degronimers for target protein degradation
JP6957518B2 (en)	2016-05-20	2021-11-02	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	A novel pyrazine compound with oxygen, sulfur and nitrogen linkers for the treatment of infectious diseases
BR102017010009A2 (en)	2016-05-27	2017-12-12	Gilead Sciences, Inc.	COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION
CN118178444A (en)	2016-05-27	2024-06-14	吉利德科学公司	Methods of treating hepatitis B virus infection using NS5A, NS5B or NS3 inhibitors
WO2017214395A1 (en)	2016-06-10	2017-12-14	Enanta Pharmaceuticals, Inc.	Hepatitis b antiviral agents
WO2017216686A1 (en)	2016-06-16	2017-12-21	Novartis Ag	8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
WO2017216685A1 (en)	2016-06-16	2017-12-21	Novartis Ag	Pentacyclic pyridone compounds as antivirals
JP7051804B2 (en)	2016-07-14	2022-04-11	エフ．ホフマン－ラロシュアーゲー	6,7-dihydro-4H-pyrazolo [1,5-a] pyrazine compound and 6,7-dihydro-4H-triazolo [1,5-a] pyrazine compound for the treatment of infectious diseases
EP3484885B1 (en)	2016-07-14	2020-03-04	H. Hoffnabb-La Roche Ag	Carboxy 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
JP6936848B2 (en)	2016-07-14	2021-09-22	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	A novel tetrahydropyrazolopyridine compound for the treatment of infectious diseases
JOP20190024A1 (en)	2016-08-26	2019-02-19	Gilead Sciences Inc	Substituted pyrrolizine compounds and uses thereof
WO2018045150A1 (en)	2016-09-02	2018-03-08	Gilead Sciences, Inc.	4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
CA3035346A1 (en)	2016-09-02	2018-03-08	Gilead Sciences, Inc.	Toll like receptor modulator compounds
WO2018047109A1 (en)	2016-09-09	2018-03-15	Novartis Ag	Polycyclic pyridone compounds as antivirals
BR112019004560A2 (en)*	2016-09-13	2019-07-02	Hoffmann La Roche	combination treatment with tlr7 agonist and a hbv capsid formation inhibitor
CN117402852A (en)	2016-10-14	2024-01-16	精密生物科学公司	Engineered meganucleases specific for recognition sequences in hepatitis b virus genomes
TW201819380A (en)	2016-10-18	2018-06-01	瑞士商諾華公司	Fused tetracyclic pyridone compounds as antivirals
CN110114071B (en)	2016-11-07	2023-07-04	爱彼特生物制药公司	Tricyclic compounds containing substituted pyridones and methods of using them
EA037576B1 (en)*	2016-11-11	2021-04-15	Новира Терапьютикс, Инк.	Combinations and methods comprising a capsid assembly inhibitor
AR110768A1 (en)	2017-01-31	2019-05-02	Gilead Sciences Inc	CRYSTAL FORMS OF TENOFOVIR ALAFENAMIDA
JOP20180008A1 (en)	2017-02-02	2019-01-30	Gilead Sciences Inc	Compounds for the treatment of hepatitis b virus infection
CA3048278A1 (en)*	2017-02-07	2018-08-16	Janssen Pharmaceutica Nv	Sulphamoylaryl derivatives and use thereof as medicaments for the treatment of liver fibrosis
EP3601216B1 (en)	2017-03-21	2023-10-25	Arbutus Biopharma Corporation	Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same for the treatment of hepatitis b virus infection
JOP20180040A1 (en)	2017-04-20	2019-01-30	Gilead Sciences Inc	Pd-1/pd-l1 inhibitors
AR111419A1 (en)	2017-04-27	2019-07-10	Novartis Ag	INDAZOL PIRIDONA FUSIONED COMPOUNDS AS ANTIVIRALS
US11591334B2 (en)	2017-05-04	2023-02-28	Shanghai Longwood Biopharmaceuticals Co., Ltd.	Substituted pyrrolizines for the treatment of hepatitis B
CN110769822A (en)	2017-06-20	2020-02-07	C4医药公司	N/O-linked degron and degron bodies for protein degradation
EP3645516A4 (en)	2017-06-27	2021-07-07	Janssen Pharmaceutica NV	Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections
CN109251158B (en)*	2017-07-14	2023-05-23	上海长森药业有限公司	Thioamidine amide compounds and use thereof for treating hepatitis B
CN109251212A (en)	2017-07-14	2019-01-22	上海长森药业有限公司	Inner ring sulfide amide-arylamides and its purposes for treating hepatitis B
RU2666727C1 (en)*	2017-07-18	2018-09-12	Андрей Александрович Иващенко	Hepatitis b (hbv) inhibitor
AR112412A1 (en)	2017-08-17	2019-10-23	Gilead Sciences Inc	CHOLINE SALT FORMS OF AN HIV CAPSID INHIBITOR
TWI687415B (en)	2017-08-17	2020-03-11	美商基利科學股份有限公司	Solid forms of an hiv capsid inhibitor
WO2019040102A1 (en)	2017-08-22	2019-02-28	Gilead Sciences, Inc.	Therapeutic heterocyclic compounds
CN111263586B (en)	2017-08-28	2021-12-03	英安塔制药有限公司	Hepatitis B antiviral agent
WO2019084060A1 (en)	2017-10-24	2019-05-02	Silverback Therapeutics, Inc.	Conjugates and methods of use thereof for selective delivery of immune-modulatory agents
SG11202003700TA (en)	2017-11-02	2020-05-28	Aicuris Gmbh & Co Kg	Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
AR115131A1 (en)	2017-11-02	2020-12-02	Aicuris Gmbh & Co Kg	HIGHLY ACTIVE INDOLO-2-CARBOXAMIDES REPLACED WITH PYRAZOLO-PYRIMIDINE ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)
EP3710455A1 (en)	2017-11-17	2020-09-23	Novartis AG	Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b
CN109879799B (en)*	2017-12-06	2020-08-11	浙江司太立制药股份有限公司	Sulfamoylbenzamide compounds containing 4-carbonyloxypiperidyl and preparation method thereof
TW201936192A (en)	2017-12-06	2019-09-16	美商因那塔製藥公司	Hepatitis B antiviral agents
TW201927789A (en)	2017-12-06	2019-07-16	美商因那塔製藥公司	Hepatitis B antiviral agents
WO2019118358A1 (en)*	2017-12-11	2019-06-20	VenatoRx Pharmaceuticals, Inc.	Hepatitis b capsid assembly modulators
JP2021506827A (en)	2017-12-15	2021-02-22	シルバーバックセラピューティックスインコーポレイテッド	Antibody constructs for the treatment of hepatitis-drug conjugates
US11203610B2 (en)	2017-12-20	2021-12-21	Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.	2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
KR102492187B1 (en)	2017-12-20	2023-01-27	인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이.	3'3' cyclic dinucleotides with phosphonate linkages that activate STING adapter proteins
US11234977B2 (en)	2017-12-20	2022-02-01	Novartis Ag	Fused tricyclic pyrazolo-dihydropyrazinyl-pyridone compounds as antivirals
WO2019143902A2 (en)	2018-01-22	2019-07-25	Enanta Pharmaceuticals, Inc.	Substituted heterocycles as antiviral agents
CN108059611A (en)*	2018-01-22	2018-05-22	济南舜景医药科技有限公司	A kind of synthetic method for being used to treat heart murmur pharmaceutical intermediate
EP4227302A1 (en)	2018-02-13	2023-08-16	Gilead Sciences, Inc.	Pd-1/pd-l1 inhibitors
EP3752495B1 (en)	2018-02-15	2023-07-19	Gilead Sciences, Inc.	Pyridine derivatives and their use for treating hiv infection
CN116854630A (en)	2018-02-16	2023-10-10	吉利德科学公司	Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviral infections
KR102526964B1 (en)	2018-02-26	2023-04-28	길리애드 사이언시즈, 인코포레이티드	Substituted pyrrolizine compounds as HBV replication inhibitors
WO2019166951A1 (en)	2018-02-28	2019-09-06	Novartis Ag	Indole-2-carbonyl compounds and their use for the treatment of hepatitis b
CA3090125A1 (en)	2018-03-14	2019-09-19	Janssen Sciences Ireland Unlimited Company	Capsid assembly modulator dosing regimen
WO2019191166A1 (en)	2018-03-29	2019-10-03	Enanta Pharmaceuticals, Inc.	Hepatitis b antiviral agents
EP3774883A1 (en)	2018-04-05	2021-02-17	Gilead Sciences, Inc.	Antibodies and fragments thereof that bind hepatitis b virus protein x
TWI833744B (en)	2018-04-06	2024-03-01	捷克科學院有機化學與生物化學研究所	3'3'-cyclic dinucleotides
TWI818007B (en)	2018-04-06	2023-10-11	捷克科學院有機化學與生物化學研究所	2'3'-cyclic dinucleotides
TW202005654A (en)	2018-04-06	2020-02-01	捷克科學院有機化學與生物化學研究所	2'2'-cyclic dinucleotides
TW201945388A (en)	2018-04-12	2019-12-01	美商精密生物科學公司	Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis B virus genome
CN112041311B (en)	2018-04-19	2023-10-03	吉利德科学公司	PD-1/PD-L1 inhibitors
TW202014193A (en)	2018-05-03	2020-04-16	捷克科學院有機化學與生物化學研究所	2’3’-cyclic dinucleotides comprising carbocyclic nucleotide
CN112585118A (en)	2018-06-11	2021-03-30	维纳拓尔斯制药公司	Hepatitis b capsid assembly modulators
SG11202012043RA (en)	2018-07-03	2021-01-28	Gilead Sciences Inc	Antibodies that target hiv gp120 and methods of use
EP3818052A1 (en)	2018-07-06	2021-05-12	Gilead Sciences, Inc.	Therapeutic heterocyclic compounds
AU2019297428C1 (en)	2018-07-06	2023-03-23	Gilead Sciences, Inc.	Therapeutic heterocyclic compounds
CA3103286C (en)	2018-07-13	2023-05-09	Gilead Sciences, Inc.	Pd-1/pd-l1 inhibitors
TWI842721B (en)	2018-07-16	2024-05-21	美商基利科學股份有限公司	Capsid inhibitors for the treatment of hiv
EP3597637A1 (en)	2018-07-19	2020-01-22	Irbm S.P.A.	Inhibitors of hepatitis b virus
EP3597653A1 (en)	2018-07-19	2020-01-22	Irbm S.P.A.	Cyclic inhibitors of hepatitis b virus
TWI826492B (en)	2018-07-27	2023-12-21	加拿大商愛彼特生物製藥公司	Substituted tetrahydrocyclopenta[c]pyrroles, substituted dihydropyrrolizines, analogues thereof, and methods using same
WO2020028097A1 (en)	2018-08-01	2020-02-06	Gilead Sciences, Inc.	Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
US11053235B2 (en)	2018-08-09	2021-07-06	Janssen Sciences Ireland Unlimited Company	Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases
EP3608326A1 (en)	2018-08-10	2020-02-12	Irbm S.P.A.	Tricyclic inhibitors of hepatitis b virus
WO2020056008A1 (en)	2018-09-12	2020-03-19	Silverback Therapeutics, Inc.	Compositions for the treatment of disease with immune stimulatory conjugates
AU2019342750A1 (en)	2018-09-21	2021-04-08	Enanta Pharmaceuticals, Inc.	Functionalized heterocycles as antiviral agents
WO2020072656A1 (en)	2018-10-03	2020-04-09	Gilead Sciences, Inc.	Imidozopyrimidine derivatives
CN112955435B (en)	2018-10-24	2024-09-06	吉利德科学公司	PD-1/PD-L1 inhibitors
DK3873903T3 (en)	2018-10-31	2024-04-02	Gilead Sciences Inc	SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS
JP7273172B2 (en)	2018-10-31	2023-05-12	ギリアードサイエンシーズ，インコーポレイテッド	Substituted 6-azabenzimidazole compounds with HPK1 inhibitory activity
UY38436A (en)	2018-11-02	2020-05-29	Aicuris Gmbh & Co Kg	NEW 6,7-DIHYDRO-4H-PYRAZOLE [1,5-A] PYRAZININDOL-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)
US20220009945A1 (en)	2018-11-02	2022-01-13	Aicuris Gmbh & Co. Kg	Novel urea 6,7-dihydro-4h-thiazole[5,4-c]pyridines active against the hepatitis b virus (hbv)
AR116948A1 (en)	2018-11-02	2021-06-30	Aicuris Gmbh & Co Kg	DERIVATIVES OF UREA 6,7-DIHIDRO-4H-PIRAZOLO [1,5-A] PYRAZINES ACTIVE AGAINST THE VIRUS OF HEPATITIS B (HBV)
AR116946A1 (en)	2018-11-02	2021-06-30	Aicuris Gmbh & Co Kg	DERIVATIVES OF UREA 6,7-DIHIDRO-4H-PIRAZOLO [4,3-C] PYRIDINES ACTIVE AGAINST THE VIRUS OF HEPATITIS B (HBV)
AR117188A1 (en)	2018-11-02	2021-07-21	Aicuris Gmbh & Co Kg	DERIVATIVES OF UREA 6,7-DIHIDRO-4H-PIRAZOLO [1,5-A] PYRAZINES ACTIVE AGAINST THE VIRUS OF HEPATITIS B (HBV)
UY38434A (en)	2018-11-02	2020-05-29	Aicuris Gmbh & Co Kg	NEW 6,7-DIHYDRO-4H-PYRAZOLE [1,5-A] PIRAZIN INDOL-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)
CN113271946A (en)	2018-11-21	2021-08-17	英安塔制药有限公司	Functionalized heterocyclic compounds as antiviral agents
KR102077833B1 (en)	2018-12-10	2020-02-14	류형준	Fuctional food compositions
TW202415643A (en)	2018-12-12	2024-04-16	加拿大商愛彼特生物製藥公司	Substituted arylmethylureas and heteroarylmethylureas, analogues thereof, and methods using same
EP3897631A4 (en)	2018-12-20	2022-11-23	C4 Therapeutics, Inc.	TARGETED PROTEIN BREAKDOWN
CN111434665B (en)	2019-01-11	2023-03-10	上海长森药业有限公司	Ensultamidenamide-arylamide compounds and their use for treating hepatitis B
JP2022521081A (en)	2019-02-22	2022-04-05	ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー	Amide derivatives useful in the treatment of HBV infections or HBV-induced diseases
WO2020176505A1 (en)	2019-02-25	2020-09-03	Gilead Sciences, Inc.	Protein kinase c agonists
WO2020176510A1 (en)	2019-02-25	2020-09-03	Gilead Sciences, Inc.	Protein kinase c agonists
US11766447B2 (en)	2019-03-07	2023-09-26	Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.	3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
AU2020231115B2 (en)	2019-03-07	2025-02-20	Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.	3'3'-cyclic dinucleotides and prodrugs thereof
WO2020178769A1 (en)	2019-03-07	2020-09-10	Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.	2'3'-cyclic dinucleotides and prodrugs thereof
CA3128961A1 (en)	2019-03-22	2020-10-01	Hang CHU	Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
TW202212339A (en)	2019-04-17	2022-04-01	美商基利科學股份有限公司	Solid forms of a toll-like receptor modulator
TWI751516B (en)	2019-04-17	2022-01-01	美商基利科學股份有限公司	Solid forms of a toll-like receptor modulator
CU20210088A7 (en)	2019-04-30	2022-06-06	Aicuris Gmbh & Co Kg	COMPOUNDS SUBSTITUTED DERIVATIVES OF INDOL-2-CARBOXAMIDES ACTIVE AGAINST HEPATITIS B VIRUS (HBV)
US20220227785A1 (en)	2019-04-30	2022-07-21	Aicuris Gmbh & Co. Kg	Novel phenyl and pyridyl ureas active against the hepatitis b virus (hbv)
JP2022533007A (en)	2019-04-30	2022-07-21	アイクリスゲゼルシャフトミットベシュレンクテルハフツングウントコンパニーコマンディトゲゼルシャフト	A novel indolizine-2-carboxamide that is active against hepatitis B virus (HBV)
KR20220003023A (en)	2019-04-30	2022-01-07	아이쿠리스 게엠베하 운트 코. 카게	Novel oxalyl piperazine active against hepatitis B virus (HBV)
TW202108576A (en)	2019-05-06	2021-03-01	愛爾蘭商健生科學愛爾蘭無限公司	Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases
TWI762925B (en)	2019-05-21	2022-05-01	美商基利科學股份有限公司	Methods of identifying hiv patients sensitive to therapy with gp120 v3 glycan-directed antibodies
TWI826690B (en)	2019-05-23	2023-12-21	美商基利科學股份有限公司	Substituted eneoxindoles and uses thereof
EP3825318A1 (en)	2019-11-25	2021-05-26	Promidis S.r.l.	Oxalamido-substituted tricyclic inhibitors of hepatitis b virus
EP3741762A1 (en)	2019-05-23	2020-11-25	Irbm S.P.A.	Oxalamido-substituted tricyclic inhibitors of hepatitis b virus
UY38705A (en)	2019-05-23	2020-12-31	Irbm S P A	TRICYCLIC INHIBITORS SUBSTITUTED WITH HEPATITIS B VIRUS OXALAMIDE
WO2020247444A1 (en)*	2019-06-03	2020-12-10	Enanta Pharmaceuticals, Inc,	Hepatitis b antiviral agents
WO2020247575A1 (en)	2019-06-04	2020-12-10	Enanta Pharmaceuticals, Inc.	Hepatitis b antiviral agents
WO2020247561A1 (en)	2019-06-04	2020-12-10	Enanta Pharmaceuticals, Inc,	Hepatitis b antiviral agents
WO2020247504A1 (en)*	2019-06-06	2020-12-10	Aligos Therapeutics, Inc.	Heterocyclic compounds
US20220305115A1 (en)	2019-06-18	2022-09-29	Janssen Sciences Ireland Unlimited Company	Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
US20220305116A1 (en)	2019-06-18	2022-09-29	Janssen Sciences lreland Unlimited Company	Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being sulfonamide derivatives
JP2022536855A (en)	2019-06-19	2022-08-19	シルバーバックセラピューティックスインコーポレイテッド	Anti-mesothelin antibodies and their immunoconjugates
CR20210687A (en)	2019-06-25	2022-03-03	Gilead Sciences Inc	FLT3L-Fc FUSION PROTEINS AND METHODS OF USE
WO2021007488A1 (en)	2019-07-11	2021-01-14	Enanta Pharmaceuticals, Inc.	Substituted heterocycles as antiviral agents
JP7454645B2 (en)	2019-07-16	2024-03-22	ギリアードサイエンシーズ，インコーポレイテッド	HIV vaccine and its production and use methods
WO2021011891A1 (en)	2019-07-18	2021-01-21	Gilead Sciences, Inc.	Long-acting formulations of tenofovir alafenamide
US20220296619A1 (en)	2019-08-19	2022-09-22	Gilead Sciences, Inc.	Pharmaceutical formulations of tenofovir alafenamide
WO2021055425A2 (en)	2019-09-17	2021-03-25	Enanta Pharmaceuticals, Inc.	Functionalized heterocycles as antiviral agents
US11497808B2 (en)	2019-09-30	2022-11-15	Gilead Sciences, Inc.	HBV vaccines and methods treating HBV
AU2020358726A1 (en)	2019-10-01	2022-04-07	Silverback Therapeutics, Inc.	Combination therapy with immune stimulatory conjugates
EP4045083B1 (en)	2019-10-18	2024-01-10	Forty Seven, Inc.	Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
JP2022552748A (en)	2019-10-31	2022-12-19	フォーティセブン，インコーポレイテッド	Treatment of hematological cancers with anti-CD47 and anti-CD20
TWI778443B (en)	2019-11-12	2022-09-21	美商基利科學股份有限公司	Mcl1 inhibitors
CN114727999A (en)	2019-11-26	2022-07-08	吉利德科学公司	Capsid inhibitors for HIV prevention
AU2020398327A1 (en)	2019-12-03	2022-07-14	Evotec International Gmbh	Interferon-associated antigen binding proteins and uses thereof
CN116057068A (en)	2019-12-06	2023-05-02	精密生物科学公司	Optimized engineered meganucleases with specificity for recognition sequences in hepatitis b virus genomes
WO2021123145A1 (en)	2019-12-19	2021-06-24	Universite De Strasbourg	Sigma-1 receptor ligands and uses thereof
PT4081305T (en)	2019-12-24	2024-12-04	Gilead Sciences Inc	Diacylglycerol kinase modulating compounds
CA3169451A1 (en)	2020-02-14	2021-08-19	Jounce Therapeutics, Inc.	Antibodies and fusion proteins that bind to ccr8 and uses thereof
JP7735291B2 (en)	2020-02-21	2025-09-08	エーアールエスファーマシューティカルズ、インコーポレイテッド	Nectin-4 antibody conjugates and uses thereof
WO2021188414A1 (en)	2020-03-16	2021-09-23	Enanta Pharmaceuticals, Inc.	Functionalized heterocyclic compounds as antiviral agents
WO2021188959A1 (en)	2020-03-20	2021-09-23	Gilead Sciences, Inc.	Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
CN111349056B (en)*	2020-04-16	2022-08-02	南京安纳康生物科技有限公司	Antiviral agent for hepatitis B virus infection
CN111393391B (en)*	2020-04-16	2022-07-26	南京安纳康生物科技有限公司	Antiviral agent for hepatitis B virus infection
CN115698009B (en)	2020-05-01	2025-04-08	吉利德科学公司	CD 73-inhibiting 2, 4-dioxopyrimidine compounds
WO2021236944A1 (en)	2020-05-21	2021-11-25	Gilead Sciences, Inc.	Pharmaceutical compositions comprising bictegravir
CA3181690A1 (en)	2020-06-25	2021-12-30	Chienhung CHOU	Capsid inhibitors for the treatment of hiv
AU2021300362A1 (en)	2020-07-01	2023-02-23	ARS Pharmaceuticals, Inc.	Anti-ASGR1 antibody conjugates and uses thereof
US20230303599A1 (en)	2020-08-07	2023-09-28	Gilead Sciences, Inc.	Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
TW202406932A (en)	2020-10-22	2024-02-16	美商基利科學股份有限公司	Interleukin-2-fc fusion proteins and methods of use
CA3195799A1 (en)	2020-11-11	2022-05-19	Stephen R. Martin	Methods of identifying hiv patients sensitive to therapy with gp120 cd4 binding site-directed antibodies
US20240209080A1 (en)	2021-04-10	2024-06-27	Profoundbio Us Co.	Folr1 binding agents, conjugates thereof and methods of using the same
TW202302145A (en)	2021-04-14	2023-01-16	美商基利科學股份有限公司	Co-inhibition of cd47/sirpα binding and nedd8-activating enzyme e1 regulatory subunit for the treatment of cancer
JP7742892B2 (en)	2021-04-23	2025-09-22	ジェンマブエー／エス	Anti-CD70 antibodies, conjugates thereof and methods of using same
WO2022241134A1 (en)	2021-05-13	2022-11-17	Gilead Sciences, Inc.	COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
WO2022245671A1 (en)	2021-05-18	2022-11-24	Gilead Sciences, Inc.	Methods of using flt3l-fc fusion proteins
EP4359413A1 (en)	2021-06-23	2024-05-01	Gilead Sciences, Inc.	Diacylglyercol kinase modulating compounds
WO2022271677A1 (en)	2021-06-23	2022-12-29	Gilead Sciences, Inc.	Diacylglyercol kinase modulating compounds
JP7651018B2 (en)	2021-06-23	2025-03-25	ギリアードサイエンシーズ，インコーポレイテッド	Diacylglycerol kinase modulating compounds
JP7654118B2 (en)	2021-06-23	2025-03-31	ギリアードサイエンシーズ，インコーポレイテッド	Diacylglycerol kinase modulating compounds
TW202320857A (en)	2021-07-06	2023-06-01	美商普方生物製藥美國公司	Linkers, drug linkers and conjugates thereof and methods of using the same
TWI857377B (en)	2021-10-28	2024-10-01	美商基利科學股份有限公司	Pyridizin-3(2h)-one derivatives
EP4422756A1 (en)	2021-10-29	2024-09-04	Gilead Sciences, Inc.	Cd73 compounds
TW202342447A (en)	2021-12-03	2023-11-01	美商基利科學股份有限公司	Therapeutic compounds for hiv virus infection
EP4440702B1 (en)	2021-12-03	2025-05-21	Gilead Sciences, Inc.	Therapeutic compounds for hiv virus infection
EP4440700A1 (en)	2021-12-03	2024-10-09	Gilead Sciences, Inc.	Therapeutic compounds for hiv virus infection
US20230220106A1 (en)	2021-12-08	2023-07-13	Dragonfly Therapeutics, Inc.	Antibodies targeting 5t4 and uses thereof
US20230203202A1 (en)	2021-12-08	2023-06-29	Dragonfly Therapeutics, Inc.	Proteins binding nkg2d, cd16 and 5t4
EP4452415A1 (en)	2021-12-22	2024-10-30	Gilead Sciences, Inc.	Ikaros zinc finger family degraders and uses thereof
JP2024546851A (en)	2021-12-22	2024-12-26	ギリアードサイエンシーズ，インコーポレイテッド	IKAROS ZINC FINGER FAMILY DEGRADANT AND USES THEREOF
TW202340168A (en)	2022-01-28	2023-10-16	美商基利科學股份有限公司	Parp7 inhibitors
PE20242225A1 (en)	2022-03-17	2024-11-19	Gilead Sciences Inc	IKAROS FAMILY ZINC FINGER DEGRADERS AND THEIR USES
US20230355796A1 (en)	2022-03-24	2023-11-09	Gilead Sciences, Inc.	Combination therapy for treating trop-2 expressing cancers
TWI876305B (en)	2022-04-05	2025-03-11	美商基利科學股份有限公司	Combination therapy for treating colorectal cancer
TWI856796B (en)	2022-04-06	2024-09-21	美商基利科學股份有限公司	Bridged tricyclic carbamoylpyridone compounds and uses thereof
IL316058A (en)	2022-04-21	2024-11-01	Gilead Sciences Inc	Kras g12d modulating compounds
EP4547657A1 (en)	2022-07-01	2025-05-07	Gilead Sciences, Inc.	Cd73 compounds
US20240034724A1 (en)	2022-07-01	2024-02-01	Gilead Sciences, Inc.	Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
AU2023307100A1 (en)	2022-07-12	2025-01-02	Gilead Sciences, Inc.	Hiv immunogenic polypeptides and vaccines and uses thereof
WO2024044477A1 (en)	2022-08-26	2024-02-29	Gilead Sciences, Inc.	Dosing and scheduling regimen for broadly neutralizing antibodies
CN115850094B (en)*	2022-09-07	2025-02-11	北华航天工业学院	A method for synthesizing β-amino alcohol using 1,2-butylene oxide
US20240091351A1 (en)	2022-09-21	2024-03-21	Gilead Sciences, Inc.	FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
US20240226130A1 (en)	2022-10-04	2024-07-11	Gilead Sciences, Inc.	4'-thionucleoside analogues and their pharmaceutical use
CN115677545B (en)*	2022-10-28	2024-03-15	潍坊医学院	An anti-HBV sulfabenzamide derivative and its preparation method and application
KR20250122479A (en)	2022-12-22	2025-08-13	길리애드 사이언시즈, 인코포레이티드	PRMT5 inhibitors and uses thereof
WO2024215754A1 (en)	2023-04-11	2024-10-17	Gilead Sciences, Inc.	Kras modulating compounds
WO2024220624A1 (en)	2023-04-19	2024-10-24	Gilead Sciences, Inc.	Dosing regimen of capsid inhibitor
WO2024220917A1 (en)	2023-04-21	2024-10-24	Gilead Sciences, Inc.	Prmt5 inhibitors and uses thereof
WO2024249573A1 (en)	2023-05-31	2024-12-05	Gilead Sciences, Inc.	Solid forms of compounds useful in the treatment of hiv
WO2024249592A1 (en)	2023-05-31	2024-12-05	Gilead Sciences, Inc.	Quinazolinyl-indazole derivatives as therapeutic compounds for hiv
US20250042922A1 (en)	2023-06-30	2025-02-06	Gilead Sciences, Inc.	Kras modulating compounds
US20250100998A1 (en)	2023-07-26	2025-03-27	Gilead Sciences, Inc.	Parp7 inhibitors
US20250066328A1 (en)	2023-07-26	2025-02-27	Gilead Sciences, Inc.	Parp7 inhibitors
WO2025029247A1 (en)	2023-07-28	2025-02-06	Gilead Sciences, Inc.	Weekly regimen of lenacapavir for the treatment and prevention of hiv
WO2025042394A1 (en)	2023-08-23	2025-02-27	Gilead Sciences, Inc.	Dosing regimen of hiv capsid inhibitor
WO2025054530A1 (en)	2023-09-08	2025-03-13	Gilead Sciences, Inc.	Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
US20250101042A1 (en)	2023-09-08	2025-03-27	Gilead Sciences, Inc.	Kras g12d modulating compounds
WO2025072406A1 (en)	2023-09-26	2025-04-03	Profoundbio Us Co.	Ptk7 binding agents, conjugates thereof and methods of using the same
US20250120989A1 (en)	2023-10-11	2025-04-17	Gilead Sciences, Inc.	Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2025080863A1 (en)	2023-10-11	2025-04-17	Gilead Sciences, Inc.	Bridged tricyclic carbamoylpyridone compounds and uses thereof
US20250127801A1 (en)	2023-10-11	2025-04-24	Gilead Sciences, Inc.	Bridged tricyclic carbamoylpyridone compounds and uses thereof
US20250154172A1 (en)	2023-11-03	2025-05-15	Gilead Sciences, Inc.	Prmt5 inhibitors and uses thereof
WO2025137245A1 (en)	2023-12-22	2025-06-26	Gilead Sciences, Inc.	Solid forms of hiv integrase inhibitors
US20250230168A1 (en)	2023-12-22	2025-07-17	Gilead Sciences, Inc.	Azaspiro wrn inhibitors
US20250296992A1 (en)	2024-01-10	2025-09-25	Genmab A/S	Slitrk6 binding agents, conjugates thereof and methods of using the same
WO2025181219A1 (en)	2024-02-29	2025-09-04	Genmab A/S	Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
WO2025184452A1 (en)	2024-03-01	2025-09-04	Gilead Sciences, Inc.	Solid forms of hiv integrase inhibitors
WO2025184609A1 (en)	2024-03-01	2025-09-04	Gilead Sciences, Inc.	Antiviral compounds
WO2025184447A1 (en)	2024-03-01	2025-09-04	Gilead Sciences, Inc.	Pharmaceutical compositions comprising hiv integrase inhibitors

Family Cites Families (247)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3843662A (en)	1971-12-09	1974-10-22	Pfizer	2-halo-5-(substituted piperidino sulfonyl)benzoic acids
AU1508183A (en)	1982-06-04	1983-12-08	Beecham Group Plc	Benzamide and anilide derivatives of 8-azabicyclo-(3.2.1)- -octane
WO1984003281A1 (en)	1983-02-19	1984-08-30	Beecham Group Plc	Azabicycloalkyl benzamide and anilide derivatives
JPS62142164A (en)	1985-12-13	1987-06-25	Ishihara Sangyo Kaisha Ltd	4,5-dichloroimidazole based compound and pest controlling agent containing said compound
IN164880B (en)	1986-01-30	1989-06-24	Ishihara Sangyo Kaisha
US5272167A (en)	1986-12-10	1993-12-21	Schering Corporation	Pharmaceutically active compounds
CA1339133C (en)	1987-03-13	1997-07-29	Rikuo Nasu	Imidazole compounds and biocidal composition comprising the same for controlling harmful organisms
US5571821A (en)	1993-05-20	1996-11-05	Texas Biotechnology Corporation	Sulfonamides and derivatives thereof that modulate the activity of endothelin
GB8904174D0 (en)	1989-02-23	1989-04-05	British Bio Technology	Compounds
US5007790A (en)	1989-04-11	1991-04-16	Depomed Systems, Inc.	Sustained-release oral drug dosage form
US4962101A (en)	1989-08-21	1990-10-09	Merck & Co., Inc.	2-(Heterocyclylalkyl)phenyl carbapenem antibacterial agents
DK0450097T3 (en)*	1989-10-20	1996-05-20	Otsuka Pharma Co Ltd	Benzoheterocyclic Compounds
US5169645A (en)	1989-10-31	1992-12-08	Duquesne University Of The Holy Ghost	Directly compressible granules having improved flow properties
GB9023082D0 (en)	1990-10-24	1990-12-05	Schering Agrochemicals Ltd	Fungicides
GB9109557D0 (en)	1991-05-02	1991-06-26	Wellcome Found	Chemical compounds
ES2124303T3 (en)	1992-03-25	1999-02-01	Depomed Inc	DOSAGE FORMS OF DELAYED DELIVERY ORAL DRUGS BASED ON HYDROXYETHYL CELLULOSE.
US5582837A (en)	1992-03-25	1996-12-10	Depomed, Inc.	Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5308826A (en)	1993-04-22	1994-05-03	Zeneca Limited	Herbicidal 4-substituted pyridyl-3-carbinols
GB9405347D0 (en)	1994-03-18	1994-05-04	Agrevo Uk Ltd	Fungicides
WO1995032949A1 (en)	1994-05-27	1995-12-07	James Black Foundation Limited	Gastrin and cck antagonists
US5795907A (en)	1994-05-27	1998-08-18	James Black Foundation Limited	Gastin and CCK receptor ligands
US5763618A (en)	1995-05-12	1998-06-09	Konica Corporation	Manufacturing method of sulfides
EP0858451A1 (en)*	1995-10-17	1998-08-19	Astra Pharmaceuticals Limited	Pharmaceutically active quinazoline compounds
US5723411A (en)	1995-10-31	1998-03-03	E. I. Du Pont De Nemours And Company	Herbicidal pyridazinones
DE19540995A1 (en)	1995-11-03	1997-05-07	Hoechst Ag	Substituted sulfonimidamides, process for their preparation, their use as a medicament or diagnostic agent, and medicament containing them
WO1997047285A1 (en)	1996-06-10	1997-12-18	Depomed, Inc.	Gastric-retentive oral controlled drug delivery system with enhanced retention properties
GB9612884D0 (en)	1996-06-20	1996-08-21	Smithkline Beecham Plc	Novel compounds
US6025367A (en)	1996-06-25	2000-02-15	Smithkline Beecham Plc	Sulfonamide derivatives as 5HT7 receptor antagonists
US5972389A (en)	1996-09-19	1999-10-26	Depomed, Inc.	Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
AU5127098A (en)	1996-11-29	1998-06-22	Smithkline Beecham Plc	Use of a combination of penciclovir and alpha-interferon in the manufacture of a medicament for the treatment of hepatitis
US5939423A (en)	1997-04-16	1999-08-17	Sciclone Pharmaceuticals, Inc.	Treatment of hepatitis B infection with thymosin alpha 1 and famciclovir
US5919970A (en)	1997-04-24	1999-07-06	Allergan Sales, Inc.	Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US6635280B2 (en)	1997-06-06	2003-10-21	Depomed, Inc.	Extending the duration of drug release within the stomach during the fed mode
JP4083818B2 (en)	1997-06-06	2008-04-30	ディポメド，インコーポレイティド	Gastric retentive oral drug dosage form for controlled release of highly soluble drugs
US5994396A (en)	1997-08-18	1999-11-30	Centaur Pharmaceuticals, Inc.	Furansulfonic acid derivatives and pharmaceutical compositions containing the same
CA2318731C (en)	1998-01-29	2012-05-29	Tularik Inc.	Ppar-gamma modulators
AU754716B2 (en)	1998-03-26	2002-11-21	Japan Tobacco Inc.	Amide derivatives and nociceptin antagonists
US6251893B1 (en)	1998-06-15	2001-06-26	Nps Allelix Corp.	Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
BR0007527B1 (en)	1999-01-15	2011-12-27		phenylphenanthridines with inhibitory activity of pde-iv, their use, as well as medicament comprising them.
KR20020015376A (en)	1999-07-16	2002-02-27	로즈 암스트롱, 크리스틴 에이. 트러트웨인	Method for Treating Chronic Pain Using MEK Inhibitors
ATE382351T1 (en)	1999-08-10	2008-01-15	Univ Oxford	LONG CHAIN N-ALKYL COMPOUNDS AND THEIR OXA DERIVATIVES FOR USE AS ANTIVIRAL AGENTS
CZ2002961A3 (en)	1999-09-17	2002-08-14	Millennium Pharmaceuticals, Inc.	Benzamides and related compounds for factor Xa inhibition
AR025884A1 (en)	1999-10-01	2002-12-18	Takeda Pharmaceutical	CYCLINE AMINE COMPOUNDS, ITS PRODUCTION AND USE
JP2004510687A (en)	1999-11-02	2004-04-08	ディポメド，インコーポレイティド	Pharmacological induction of delivery mode for enhanced gastric drug administration
AU2018301A (en)	1999-12-28	2001-07-24	Pfizer Products Inc.	Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
WO2001055121A1 (en)	2000-01-28	2001-08-02	Kaken Pharmaceutical Co., Ltd.	Azepine derivatives
AU767812B2 (en)	2000-02-04	2003-11-27	Depomed, Inc.	Shell-and-core dosage form approaching zero-order drug release
US6511980B2 (en)	2000-05-05	2003-01-28	Ortho Mcneil Pharmaceutical, Inc.	Substituted diamine derivatives useful as motilin antagonists
US6488962B1 (en)	2000-06-20	2002-12-03	Depomed, Inc.	Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
EP1193268A1 (en)	2000-09-27	2002-04-03	Applied Research Systems ARS Holding N.V.	Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein Junkinases
US6451808B1 (en)	2000-10-17	2002-09-17	Depomed, Inc.	Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
WO2002051410A2 (en)	2000-12-22	2002-07-04	Akzo Nobel N.V.	Phenylthiazole and thiazoline derivatives and their use as antiparasitics
EP1357123B8 (en)	2000-12-27	2006-02-01	Dainippon Sumitomo Pharma Co., Ltd.	Novel carbapenem, medical and antibacterial comprisisng the same, and uses thereof
US7015012B2 (en)	2001-02-09	2006-03-21	Massachusetts Institute Of Technology	Methods of identifying agents that mediate polypeptide aggregation
US6650463B2 (en)	2001-03-13	2003-11-18	Seiko Epson Corporation	Electrophoretic display device
JP4220249B2 (en)	2001-04-19	2009-02-04	エーザイ・アール・アンド・ディー・マネジメント株式会社	Cyclic amidine derivatives
EP1401423A4 (en)	2001-05-29	2006-08-16	Depomed Dev Ltd	Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
KR100713137B1 (en)	2001-06-28	2007-05-02	동화약품공업주식회사	Novel 2,4-difluorobenzamide derivatives
WO2003007955A2 (en)	2001-07-20	2003-01-30	Cancer Research Technology Limited	Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
DE10136043A1 (en)	2001-07-25	2003-02-13	Degussa	Process for the production of modified carbon black
US6956035B2 (en)	2001-08-31	2005-10-18	Inotek Pharmaceuticals Corporation	Isoquinoline derivatives and methods of use thereof
US6723340B2 (en)	2001-10-25	2004-04-20	Depomed, Inc.	Optimal polymer mixtures for gastric retentive tablets
CA2409552A1 (en)	2001-10-25	2003-04-25	Depomed, Inc.	Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
WO2003035039A1 (en)	2001-10-25	2003-05-01	Depomed, Inc.	Methods of treatment using a gastric retained losartan dosage
US20030091630A1 (en)	2001-10-25	2003-05-15	Jenny Louie-Helm	Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
TWI312285B (en)	2001-10-25	2009-07-21	Depomed Inc	Methods of treatment using a gastric retained gabapentin dosage
ATE297925T1 (en)	2001-11-20	2005-07-15	Lilly Co Eli	3-SUBSTITUTED OXINDOL BETA 3 AGONISTS
US6682759B2 (en)	2002-02-01	2004-01-27	Depomed, Inc.	Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
SE0201635D0 (en)	2002-05-30	2002-05-30	Astrazeneca Ab	Novel compounds
TW200410671A (en)*	2002-06-05	2004-07-01	Inst Med Molecular Design Inc	Medicines for inhibiting the activation of AP-1
KR101124245B1 (en)	2002-06-27	2012-07-02	노보 노르디스크 에이/에스	Aryl carbonyl derivatives as therapeutic agents
WO2004002481A1 (en)	2002-06-27	2004-01-08	Novo Nordisk A/S	Aryl carbonyl derivatives as therapeutic agents
WO2004010943A2 (en)	2002-07-31	2004-02-05	Smithkline Beecham Corporation	Substituted benzanilides as modulators of the ccr5 receptor
AU2003254177A1 (en)	2002-07-31	2004-02-16	Smithkline Beecham Corporation	Substituted benzanilides as modulators of the ccr5 receptor
US7186735B2 (en)	2002-08-07	2007-03-06	Sanofi-Aventis Deutschland Gmbh	Acylated arylcycloalkylamines and their use as pharmaceuticals
US7338956B2 (en)	2002-08-07	2008-03-04	Sanofi-Aventis Deutschland Gmbh	Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
AU2003252738A1 (en)	2002-08-09	2004-02-25	Ajinomoto Co., Inc.	Remedy for intestinal diseases and visceral pain
US20050113450A1 (en)*	2002-08-23	2005-05-26	Atli Thorarensen	Antibacterial agents
US20040110802A1 (en)	2002-08-23	2004-06-10	Atli Thorarensen	Antibacterial benzoic acid derivatives
MXPA05002575A (en)	2002-09-06	2005-09-08	Johnson & Johnson	(1h-benzoimidazol-2-yl)-(piperazinyl)-methanone derivatives and related compounds as histamine h4-receptor antagonists for the treatment of inflammatory and allergic disorders.
SE0202838D0 (en)	2002-09-24	2002-09-24	Astrazeneca Ab	Chemical compounds
WO2004058709A1 (en)	2002-12-23	2004-07-15	Millennium Pharmaceuticals, Inc.	Ccr8 inhibitors
TW200503994A (en)*	2003-01-24	2005-02-01	Novartis Ag	Organic compounds
US7320989B2 (en)	2003-02-28	2008-01-22	Encysive Pharmaceuticals, Inc.	Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
JP4969238B2 (en)	2003-03-27	2012-07-04	サイトキネティクス・インコーポレーテッド	Compounds, compositions and methods
EP1628970A2 (en)	2003-04-30	2006-03-01	The Institutes of Pharmaceutical Discovery, LLC	Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
JP2006528685A (en)	2003-05-06	2006-12-21	スミスクラインビーチャムコーポレーション	New compounds
PE20050555A1 (en)	2003-05-13	2005-07-19	Schering Corp	N-ARYLSULFONYLPIPERIDINE BRIDGED COMPOUNDS AS GAMMA-SECRETASE INHIBITORS
WO2005007621A2 (en)	2003-05-30	2005-01-27	Rigel Pharmaceuticals, Inc.	Ubiquitin ligase inhibitors
US20110275630A1 (en)	2003-06-02	2011-11-10	Abbott Laboratories	Isoindolinone kinase inhibitors
AR045047A1 (en)	2003-07-11	2005-10-12	Arena Pharm Inc	ARILO AND HETEROARILO DERIVATIVES TRISUSTITUIDOS AS MODULATORS OF METABOLISM AND PROFILAXIS AND TREATMENT OF DISORDERS RELATED TO THEMSELVES
GB0319151D0 (en)	2003-08-14	2003-09-17	Glaxo Group Ltd	Novel compounds
EP1678147B1 (en)	2003-09-15	2012-08-08	Lead Discovery Center GmbH	Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
GB0325956D0 (en)	2003-11-06	2003-12-10	Addex Pharmaceuticals Sa	Novel compounds
US7498050B2 (en)	2003-12-15	2009-03-03	Kraft Foods Global Brands Llc	Edible spread composition and packaged product
DE102004009238A1 (en)	2004-02-26	2005-09-08	Merck Patent Gmbh	New aryl amide compounds are kinase inhibitors useful for the treatment and/or prophylaxis of e.g. tumors, psoriasis, rheumatoid arthritis, contact dermatitis, inflammations, endometriosis, scar and benign prostatic hyperplasia
US8404747B2 (en)	2004-03-05	2013-03-26	The General Hospital Corporation	Compositions and methods for modulating interaction between polypeptides
WO2005105785A2 (en)	2004-05-04	2005-11-10	Novo Nordisk A/S	Indole derivatives for treatment of obesity
EP1758571A1 (en)	2004-05-29	2007-03-07	7TM Pharma A/S	Crth2 receptor ligands for therapeutic use
CA2571058A1 (en)	2004-06-22	2006-01-05	Schering Corporation	Cannabinoid receptor ligands
SI1773768T1 (en)	2004-07-30	2018-12-31	Exelixis, Inc.	Pyrrole derivatives as pharmaceutical agents
DE102004042441A1 (en)	2004-08-31	2006-04-06	Sanofi-Aventis Deutschland Gmbh	Amino acid substituted hexahydro-pyrazino (1,2-a) pyrimidine-4,7-dione derivatives, process for their preparation and their use as medicaments
NZ553087A (en)	2004-08-31	2010-12-24	Astrazeneca Ab	Quinazolinone derivatives and their use as B-raf inhibitors
PA8649401A1 (en)	2004-10-13	2006-09-22	Wyeth Corp	ANILINO-PYRIMIDINE ANALOGS
CN101233115A (en)	2004-10-19	2008-07-30	诺华疫苗和诊断公司	Indole and benzimidazole derivatives
TW200628463A (en)	2004-11-10	2006-08-16	Synta Pharmaceuticals Corp	Heteroaryl compounds
US20060122236A1 (en)	2004-12-06	2006-06-08	Wood Michael R	Substituted biaryl-carboxylate derivatives
AR054183A1 (en)*	2004-12-22	2007-06-06	Astrazeneca Ab	DERIVATIVES OF PIRIDINCARBOXAMIDA AND ITS USE AS ANTICANCERIGEN AGENTS. PROCESSES OF OBTAINING AND PHARMACEUTICAL COMPOSITIONS.
WO2006067445A2 (en)*	2004-12-22	2006-06-29	Astrazeneca Ab	Csf-1r kinase inhibitors
FI117653B (en)	2005-02-21	2006-12-29	Eigenor Oy	Procedure and arrangement for sensing objects with a radar
GB0510141D0 (en)	2005-05-18	2005-06-22	Addex Pharmaceuticals Sa	Novel compounds B3
WO2006128129A2 (en)	2005-05-26	2006-11-30	Synta Pharmaceuticals Corp.	Method for treating cancer
US20070032493A1 (en)	2005-05-26	2007-02-08	Synta Pharmaceuticals Corp.	Method for treating B cell regulated autoimmune disorders
US7790726B2 (en)	2005-08-16	2010-09-07	Chemocentryx, Inc.	Monocyclic and bicyclic compounds and methods of use
DK1940786T3 (en)	2005-09-16	2010-11-08	Arrow Therapeutics Ltd	Biphenyl derivatives and their use in the treatment of hepatitis C
US7629340B2 (en)*	2005-12-12	2009-12-08	Smithkline Beecham Corporation	N-(6-membered aromatic ring)-amido anti-viral compounds
EP1962835A2 (en)	2005-12-21	2008-09-03	Schering Corporation	Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or h3 receptor antagonist/inverse agonist
EP1981849A1 (en)	2005-12-29	2008-10-22	LEK Pharmaceuticals D.D.	Heterocyclic compounds
WO2007131168A2 (en)	2006-05-04	2007-11-15	Institute For Hepatitis And Virus Research	Inhibitors of secretion of hepatitis b virus antigens for treatment of a chronic hepatitis virus
US20080021063A1 (en)	2006-07-18	2008-01-24	Kazantsev Aleksey G	Compositions and methods for modulating sirtuin activity
US8153803B2 (en)	2006-07-18	2012-04-10	The General Hospital Corporation	Compositions and methods for modulating sirtuin activity
FR2903985B1 (en)	2006-07-24	2008-09-05	Sanofi Aventis Sa	N- (AMINO-HETEROARYL) -1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
CA2658877C (en)*	2006-07-24	2013-02-19	University Of Maryland, Baltimore	Heme oxygenase inhibitors for the treatment of a microbial infection
FR2904316B1 (en)	2006-07-31	2008-09-05	Sanofi Aventis Sa	N- (AMINO-HETEROARYL) -1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE.
US20100016310A1 (en)	2006-08-17	2010-01-21	Boehringer Ingelheim International Gmbh	Methods of using aryl sulfonyl compounds effective as soluble epoxide hydrolase inhibitors
EP2091527B1 (en)	2006-12-13	2016-03-23	Temple University - Of The Commonwealth System of Higher Education	Sulfide, sulfoxide and sulfone chalcone analogues, derivatives thereof and therapeutic uses thereof
US20100022517A1 (en)	2006-12-18	2010-01-28	Richards Lori A	Ophthalmic formulation of rho kinase inhibitor compound
US8071779B2 (en)	2006-12-18	2011-12-06	Inspire Pharmaceuticals, Inc.	Cytoskeletal active rho kinase inhibitor compounds, composition and use
FR2910473B1 (en)	2006-12-26	2009-02-13	Sanofi Aventis Sa	N- (AMINO-HETEROARYL) -1H-PYRROLOPYRIDINE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE.
JP2008179621A (en)	2006-12-28	2008-08-07	Taisho Pharmaceutical Co Ltd	Nitrogen-containing saturated heterocyclic compounds
JP2008184403A (en)*	2007-01-29	2008-08-14	Japan Health Science Foundation	Novel hepatitis C virus inhibitor
CN101657430B (en)	2007-03-15	2013-05-01	诺瓦提斯公司	Organic compounds and uses thereof
JP2008266321A (en)*	2007-03-28	2008-11-06	Santen Pharmaceut Co Ltd	Intraocular pressure-reducing agent containing phenylenediamine derivative as active ingredient
US8183236B2 (en)*	2007-04-12	2012-05-22	University Of Southern California	Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics
US8097728B2 (en)	2007-04-30	2012-01-17	Philadelphia Health & Education Corporation	Iminosugar compounds with antiflavirus activity
JP5160637B2 (en)*	2007-05-04	2013-03-13	アイアールエム・リミテッド・ライアビリティ・カンパニー	Compounds and compositions as c-kit and PDGFR kinase inhibitors
EA200971143A1 (en)*	2007-06-03	2010-06-30	Вандербилт Юниверсити	BENZAMIDE MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS FOR THEIR RECEIVING AND APPLICATION
WO2008154819A1 (en)	2007-06-18	2008-12-24	Zhang, Zhongneng	Carbethoxy-substituted thiazolyl dihydropyrimidines
WO2009018219A2 (en)*	2007-07-28	2009-02-05	University Of Chicago	Methods and compositions for modulating rad51 and homologous recombination
AU2008281877A1 (en)	2007-08-02	2009-02-05	F. Hoffmann-La Roche Ag	The use of benzamide derivatives for the treatment of CNS disorders
US8377992B2 (en)*	2007-10-22	2013-02-19	The Wistar Institute	TRBD-binding effectors and methods for using the same to modulate telomerase activity
CN101429166B (en)	2007-11-07	2013-08-21	上海特化医药科技有限公司	Quinazoline ketone derivant, preparation method and application thereof
US8642660B2 (en)	2007-12-21	2014-02-04	The University Of Rochester	Method for altering the lifespan of eukaryotic organisms
FR2926554B1 (en)	2008-01-22	2010-03-12	Sanofi Aventis	AZABICYCLIC CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF
FR2926556B1 (en)	2008-01-22	2010-02-19	Sanofi Aventis	N-AZABICYCLIC CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
FR2926555B1 (en)	2008-01-22	2010-02-19	Sanofi Aventis	BICYCLIC DERIVATIVES OF AZABICYCLIC CARBOXAMIDES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
FR2926553B1 (en)	2008-01-23	2010-02-19	Sanofi Aventis	SILANYL SUBSTITUTED INDOLE-2-CARBOXAMIDE AND AZAINDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
EP2247600A4 (en)*	2008-02-06	2011-09-14	Biomarin Pharm Inc	BENZOXAZOLEBOXYLIC ACID AMIDE AS INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE (PARP)
CU20080028A6 (en)	2008-02-29	2011-02-24	Ct Ingenieria Genetica Biotech	CHEMICAL COMPOUNDS OBTAINED IN SILICO FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS TO ATTENE OR INHIBIT INFECTION BY DENGUE VIRUSES AND OTHER FLAVIVIRUS
WO2009146013A1 (en)	2008-03-31	2009-12-03	Georgetown University	Myosin light chain phosphatase inhibitors
CN102083850B (en)*	2008-04-21	2015-08-12	加利福尼亚大学董事会	Selective high-affinity multidentate ligand and its preparation method
AU2009239116B2 (en)*	2008-04-24	2013-05-30	Msd K.K.	Long-chain fatty acid elongation enzyme inhibitor comprising arylsulfonyl derivative as active ingredient
US20090325960A1 (en)	2008-06-26	2009-12-31	Fulcher Emilee H	Method for treating inflammatory diseases using rho kinase inhibitor compounds
US8207195B2 (en)	2008-06-26	2012-06-26	Inspire Pharmaceuticals, Inc.	Method for treating neurological and neuropathic diseases using rho kinase inhibitor compounds
US8410147B2 (en)	2008-06-26	2013-04-02	Inspire Pharmaceuticals, Inc.	Method for treating diseases associated with alterations in cellular integrity using Rho kinase inhibitor compounds
WO2009158587A1 (en)	2008-06-26	2009-12-30	Inspire Pharmaceuticals, Inc.	Method for treating pulmonary diseases using rho kinase inhibitor compounds
US20090325959A1 (en)	2008-06-26	2009-12-31	Vittitow Jason L	Method for treating ophthalmic diseases using rho kinase inhibitor compounds
US20100008968A1 (en)	2008-06-26	2010-01-14	Lampe John W	Method for treating cardiovascular diseases using rho kinase inhibitor compounds
AU2009276744A1 (en)*	2008-07-28	2010-02-04	Polymedix, Inc.	Anti-malarial compounds
JP2012500189A (en)	2008-08-15	2012-01-05	エフ．ホフマン−ラロシュアーゲー	Biarylaminotetralin
WO2010027996A1 (en)	2008-09-02	2010-03-11	Institute For Hepatitis And Virus Research	Novel imino sugar derivatives demonstrate potent antiviral activity and reduced toxicity
US8143269B2 (en)	2008-10-03	2012-03-27	Calcimedica, Inc.	Inhibitors of store operated calcium release
WO2010043592A1 (en)	2008-10-15	2010-04-22	Revotar Biopharmaceuticals Ag	Lipase inhibitors for use for the treatment of obesity
WO2010059658A1 (en)	2008-11-20	2010-05-27	Glaxosmithkline Llc	Chemical compounds
CN102271763A (en)*	2008-12-03	2011-12-07	麻省理工学院	Inhibits HDAC2 to promote memory
EP2400969A4 (en)	2008-12-04	2012-05-16	Inspire Pharmaceuticals Inc	Method for treating pulmonary diseases using rho kinase inhibitor compounds
WO2010078430A1 (en)	2008-12-30	2010-07-08	Arqule, Inc.	Substituted 1h-pyrazolo[3,4-d]pyrimidine-6-amine compounds
WO2010088000A2 (en)	2009-02-02	2010-08-05	Angion Biomedica Corp.	Antifibrotic compounds and uses thereof
WO2010123139A1 (en)	2009-04-24	2010-10-28	持田製薬株式会社	Arylcarboxamide derivative having sulfamoyl group
WO2010129681A1 (en)*	2009-05-05	2010-11-11	Van Andel Research Institute	Methods for treating autophagy-related disorders
JP2012527414A (en)	2009-05-19	2012-11-08	バイエル・クロップサイエンス・アーゲー	Insecticidal arylpyrroline
MX336687B (en)*	2009-06-30	2016-01-28	Siga Technologies Inc	Treatment and prevention of dengue virus infections.
US8703938B2 (en)	2009-09-11	2014-04-22	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US8822700B2 (en)	2009-09-11	2014-09-02	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
WO2011035143A2 (en)	2009-09-17	2011-03-24	The Regents Of The University Of Michigan	Methods and compositions for inhibiting rho-mediated diseases and conditions
US9051296B2 (en)	2009-11-16	2015-06-09	Raqualia Pharma Inc.	Aryl carboxamide derivatives as TTX-S blockers
CN102093320B (en)*	2009-12-09	2013-08-28	扬子江药业集团上海海尼药业有限公司	Soluble epoxide hydrolase inhibitor
EP2332528A1 (en)*	2009-12-14	2011-06-15	Grünenthal GmbH	Substituted aromatic dicarbonic acid amides as medicaments
JP2013517271A (en)	2010-01-15	2013-05-16	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Compounds that modulate the CB2 receptor
WO2011088561A1 (en)*	2010-01-20	2011-07-28	University Of Manitoba	Anti-viral compounds and compositions
US20130045203A1 (en)	2010-03-02	2013-02-21	Emory University	Uses of Noscapine and Derivatives in Subjects Diagnosed with FAP
CN102906080A (en)	2010-03-11	2013-01-30	百时美施贵宝公司	Compounds for the treatment of hepatitis C
CN102206172B (en)	2010-03-30	2015-02-25	中国医学科学院医药生物技术研究所	Substituted diaryl compound and preparation method and antiviral application thereof
JP2013523766A (en)	2010-03-31	2013-06-17	グラクソグループリミテッド	Imidazolyl-imidazole as a kinase inhibitor
UA110112C2 (en)	2010-05-07	2015-11-25	Глаксосмітклайн Ллс	INDOLES
WO2011146748A1 (en)*	2010-05-21	2011-11-24	New York University	Method of treating cancer by inhibition of protein kinase-like endoplasmic reticulum protein kinase
EP2580190A4 (en)	2010-06-11	2014-04-16	Goeran Wadell	New antiviral compounds
WO2011163593A2 (en)	2010-06-25	2011-12-29	Philadelphia Health & Education Corporation D/B/A Drexel	Induction of immune response
BR112013001125A2 (en)	2010-07-19	2016-05-17	Inspire Pharmaceuticals Inc	bifunctional rho kinase inhibiting compounds, composition and use
JP2013536178A (en)	2010-07-26	2013-09-19	ニューロセラピューティクスファーマ，インコーポレイテッド	Arylsulfonamide derivatives, compositions, and methods of use
KR20130095263A (en)	2010-07-27	2013-08-27	인스파이어 파마슈티컬스 인코퍼레이티드	Method for treating ophthalmic diseases using kinase inhibitor compounds in prodrug forms
WO2012016133A2 (en)	2010-07-29	2012-02-02	President And Fellows Of Harvard College	Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
WO2012033956A1 (en)	2010-09-08	2012-03-15	Mithridion, Inc.	Cognition enhancing compounds and compositions, methods of making, and methods of treating
US8921381B2 (en)	2010-10-04	2014-12-30	Baruch S. Blumberg Institute	Inhibitors of secretion of hepatitis B virus antigens
GB201017345D0 (en)	2010-10-14	2010-11-24	Proximagen Ltd	Receptor antagonists
EP2646439B1 (en)	2010-12-02	2016-05-25	Bristol-Myers Squibb Company	Alkyl amides as hiv attachment inhibitors
WO2012080050A1 (en)	2010-12-14	2012-06-21	F. Hoffmann-La Roche Ag	Solid forms of a phenoxybenzenesulfonyl compound
GB201103419D0 (en)	2011-02-28	2011-04-13	Univ Aberdeen
SMT201800527T1 (en)	2011-04-08	2018-11-09	Janssen Sciences Ireland Uc	Pyrimidine derivatives for the treatment of viral infections
US8889716B2 (en)	2011-05-10	2014-11-18	Chdi Foundation, Inc.	Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof
EP2726459B1 (en)	2011-07-01	2019-09-11	Baruch S. Blumberg Institute	Sulfamoylbenzamide derivatives as antiviral agents against hbv infection
TWI622578B (en)	2011-12-21	2018-05-01	諾維拉治療公司	Hepatitis b antiviral agents
WO2013102655A1 (en)	2012-01-06	2013-07-11	Janssen R&D Ireland	4,4-disubstituted-1,4-dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis b
US9657013B2 (en)	2012-02-29	2017-05-23	Baruch S. Blumberg Institute	Inhibitors of hepatitis B virus covalently closed circular DNA formation and their method of use
US20130267517A1 (en)	2012-03-31	2013-10-10	Hoffmann-La Roche Inc.	Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
CA2865259A1 (en)	2012-03-31	2013-10-03	F. Hoffmann-La Roche Ag	Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
US9422323B2 (en)	2012-05-25	2016-08-23	Janssen Sciences Ireland Uc	Uracyl spirooxetane nucleosides
US9623071B2 (en)	2012-06-01	2017-04-18	Drexel University	Modulation of hepatitis B virus CCCDNA transcription
JO3300B1 (en)	2012-06-06	2018-09-16	Novartis Ag	Compounds and compositions for modulating egfr activity
TW201408652A (en)	2012-07-11	2014-03-01	Hoffmann La Roche	Aryl sultam derivatives as RORc modulators
UA123256C2 (en)	2012-08-28	2021-03-10	ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі	SULFAMOYLARYLAMIDES AND THEIR USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
MY174042A (en)	2012-08-28	2020-03-05	Janssen Sciences Ireland Uc	Fused bicyclic sulfamoyl derivative and the use thereof as medicaments for the treatment of hepatitis b.
KR20150054795A (en)	2012-09-10	2015-05-20	에프. 호프만-라 로슈 아게	6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
US9938236B2 (en)	2012-12-27	2018-04-10	Drexel University	Antiviral agents against HBV infection
PT2961732T (en)	2013-02-28	2017-06-26	Janssen Sciences Ireland Uc	Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
RU2659219C2 (en)	2013-02-28	2018-06-29	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Tetrahydroimidazo[1,5-d][1,4]oxazepine derivative
WO2014165128A2 (en)	2013-03-12	2014-10-09	Novira Therapeutics, Inc.	Hepatitis b antiviral agents
US9944658B2 (en)	2013-03-14	2018-04-17	VenatoRx Pharmaceuticals, Inc.	Beta-lactamase inhibitors
DK2981536T3 (en)	2013-04-03	2017-09-25	Janssen Sciences Ireland Uc	N-PHENYLC CARBOXAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
JP6533217B2 (en)	2013-05-17	2019-06-19	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	6-Bridged Heteroaryldihydropyrimidines for the Treatment and Prevention of Hepatitis B Virus Infection
JO3603B1 (en)	2013-05-17	2020-07-05	Janssen Sciences Ireland Uc	Sulfamoyl pyrolamide derivatives and their use as medicines to treat hepatitis B
CA2909742C (en)	2013-05-17	2020-08-04	Janssen Sciences Ireland Uc	Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
CA2911859A1 (en)	2013-05-28	2014-12-04	Astrazeneca Ab	Chemical compounds
KR20160012170A (en)	2013-05-28	2016-02-02	바이엘 크롭사이언스 악티엔게젤샤프트	Heterocyclic compounds as pest control agents
WO2014198880A1 (en)	2013-06-14	2014-12-18	Ferrer Internacional, S.A.	2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
DK3024819T3 (en)	2013-07-25	2018-06-06	Janssen Sciences Ireland Uc	GLYOXAMIDE-SUBSTITUTED PYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B
WO2015055764A1 (en)	2013-10-18	2015-04-23	Syngenta Participations Ag	3-methanimidamid-pyridine derivatives as fungicides
CA2927560A1 (en)	2013-10-18	2015-04-23	Indiana University Research And Technology Corporation	Hepatitis b viral assembly effectors
AU2014338947B2 (en)	2013-10-23	2018-02-22	Janssen Sciences Ireland Uc	Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
EA201690979A1 (en)	2013-11-14	2016-08-31	Новира Терапьютикс, Инк.	AZEPAN DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS
JO3466B1 (en)	2013-12-20	2020-07-05	Takeda Pharmaceuticals Co	Tetrahydropyridopyrazines modulators of gpr6
US9169212B2 (en)	2014-01-16	2015-10-27	Novira Therapeutics, Inc.	Azepane derivatives and methods of treating hepatitis B infections
JP6517827B2 (en)	2014-01-31	2019-05-22	コグニションセラピューティクス，インコーポレイテッド	Isoindoline compositions and methods of treating neurodegenerative diseases
CN110483484A (en)	2014-02-06	2019-11-22	爱尔兰詹森科学公司	Sulfamoyl pyrrole amides derivative and its purposes for being used to treat hepatitis B as drug
MX350439B (en)	2014-03-07	2017-09-06	Hoffmann La Roche	Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection.
JP6602311B2 (en)	2014-03-13	2019-11-06	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーション	Hepatitis B core protein allosteric modulator
CA2938050A1 (en)	2014-03-28	2015-10-01	Sunshine Lake Pharma Co., Ltd.	Dihydropyrimidine compounds and their application in pharmaceuticals
NZ727601A (en)	2014-05-30	2022-01-28	Qilu Pharmaceutical Co Ltd	Dihydropyrimido fused ring derivative as hbv inhibitor
CN107406378A (en)	2014-12-02	2017-11-28	诺维拉治疗公司	Sulfated alkyl compounds and pyridine trans-sulfonamide compounds for HBV treatment
WO2016109684A2 (en)	2014-12-30	2016-07-07	Novira Therapeutics, Inc.	Derivatives and methods of treating hepatitis b infections
MA41338B1 (en)	2015-01-16	2019-07-31	Hoffmann La Roche	Pyrazine compounds for the treatment of infectious diseases
HK1247147A1 (en)	2015-03-19	2018-09-21	诺维拉治疗公司	Azocane and azonane derivatives and methods of treating hepatitis b infections
WO2016161268A1 (en)	2015-04-01	2016-10-06	Enanta Pharmaceuticals, Inc.	Hepatitis b antviral agents
WO2016168619A1 (en)	2015-04-17	2016-10-20	Indiana University Research And Technology Corporation	Hepatitis b viral assembly effectors
US10738035B2 (en)	2015-05-13	2020-08-11	Enanta Pharmaceuticals, Inc.	Hepatitis B antiviral agents
US10875876B2 (en)	2015-07-02	2020-12-29	Janssen Sciences Ireland Uc	Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
HK1259410A1 (en)	2015-09-29	2019-11-29	诺维拉治疗公司	Crystalline forms of a hepatitis b antiviral agent

2012
- 2012-12-21TWTW106101727Apatent/TWI622578B/ennot_activeIP Right Cessation
- 2012-12-21AUAU2012358332Apatent/AU2012358332C1/ennot_activeCeased
- 2012-12-21USUS13/723,869patent/US8629274B2/enactiveActive
- 2012-12-21JPJP2014548939Apatent/JP5977837B2/ennot_activeExpired - Fee Related
- 2012-12-21EPEP12859684.8Apatent/EP2794565B1/enactiveActive
- 2012-12-21BRBR112014015197Apatent/BR112014015197A2/ennot_activeApplication Discontinuation
- 2012-12-21EPEP17182494.9Apatent/EP3312160B1/enactiveActive
- 2012-12-21WOPCT/US2012/071195patent/WO2013096744A1/enactiveApplication Filing
- 2012-12-21KRKR1020197001059Apatent/KR20190007106A/ennot_activeCeased
- 2012-12-21EAEA201491223Apatent/EA026368B1/ennot_activeIP Right Cessation
- 2012-12-21MXMX2014007261Apatent/MX359634B/enactiveIP Right Grant
- 2012-12-21TWTW104135143Apatent/TWI580668B/ennot_activeIP Right Cessation
- 2012-12-21ESES17182494Tpatent/ES2797123T3/enactiveActive
- 2012-12-21TWTW101149112Apatent/TWI519515B/ennot_activeIP Right Cessation
- 2012-12-21ARARP120104951Apatent/AR090044A1/enunknown
- 2012-12-21SGSG11201402660YApatent/SG11201402660YA/enunknown
- 2012-12-21KRKR1020147020281Apatent/KR101699822B1/ennot_activeExpired - Fee Related
- 2012-12-21ESES12859684.8Tpatent/ES2649410T3/enactiveActive
- 2012-12-21KRKR1020177001550Apatent/KR101939710B1/ennot_activeExpired - Fee Related
- 2012-12-21CNCN201280063011.3Apatent/CN104144913B/ennot_activeExpired - Fee Related
- 2012-12-21EAEA201691837Apatent/EA037918B1/enunknown
- 2012-12-21CACA2857344Apatent/CA2857344C/ennot_activeExpired - Fee Related
- 2012-12-21CNCN201710240957.7Apatent/CN106957282B/ennot_activeExpired - Fee Related
- 2012-12-21SGSG10201608528YApatent/SG10201608528YA/enunknown
- 2012-12-21DKDK12859684.8Tpatent/DK2794565T3/enactive
2013
- 2013-12-09USUS14/100,219patent/US9061008B2/ennot_activeExpired - Fee Related
- 2013-12-19USUS14/134,113patent/US9066932B2/ennot_activeExpired - Fee Related
2014
- 2014-06-04CLCL2014001463Apatent/CL2014001463A1/enunknown
- 2014-06-10PHPH12014501314Apatent/PH12014501314A1/enunknown
- 2014-06-12COCO14127791Apatent/CO7051027A2/enactiveIP Right Grant
- 2014-06-17ILIL233182Apatent/IL233182A0/enunknown
- 2014-10-17USUS14/517,606patent/US9751857B2/ennot_activeExpired - Fee Related
2015
- 2015-06-02USUS14/728,126patent/US9676747B2/ennot_activeExpired - Fee Related
2016
- 2016-07-22JPJP2016144067Apatent/JP6553551B2/ennot_activeExpired - Fee Related
- 2016-09-23AUAU2016231615Apatent/AU2016231615B2/ennot_activeCeased
2017
- 2017-06-02USUS15/612,240patent/US10196376B2/ennot_activeExpired - Fee Related
2018
- 2018-05-14AUAU2018203354Apatent/AU2018203354B2/ennot_activeCeased
- 2018-06-19JPJP2018115795Apatent/JP2018172399A/enactivePending
- 2018-10-23HKHK18113548.0Apatent/HK1254462A1/enunknown

Also Published As

Publication number	Publication date
AU2016231615A1 (en)	2016-10-20
TW201728571A (en)	2017-08-16
KR20190007106A (en)	2019-01-21
US20140178337A1 (en)	2014-06-26
IL233182A0 (en)	2014-08-03
NZ724493A (en)	2018-06-29
ES2797123T3 (en)	2020-12-01
AU2016231615B2 (en)	2018-06-07
CN104144913A (en)	2014-11-12
EA037918B1 (en)	2021-06-07
US9066932B2 (en)	2015-06-30
TWI519515B (en)	2016-02-01
TWI580668B (en)	2017-05-01
US20130251673A1 (en)	2013-09-26
CN104144913B (en)	2017-05-17
CN106957282B (en)	2019-08-30
TW201604179A (en)	2016-02-01
AU2012358332C1 (en)	2017-01-19
CL2014001463A1 (en)	2014-12-26
EP3312160B1 (en)	2020-03-18
HK1254462A1 (en)	2019-07-19
US9751857B2 (en)	2017-09-05
JP5977837B2 (en)	2016-08-24
KR20140138602A (en)	2014-12-04
NZ625614A (en)	2016-10-28
AU2018203354A1 (en)	2018-05-31
CA2857344C (en)	2019-02-12
EA026368B1 (en)	2017-03-31
AU2018203354B2 (en)	2019-12-05
KR101699822B1 (en)	2017-01-25
WO2013096744A1 (en)	2013-06-27
EA201491223A1 (en)	2015-01-30
TW201336814A (en)	2013-09-16
CA2857344A1 (en)	2013-06-27
US10196376B2 (en)	2019-02-05
AR090044A1 (en)	2014-10-15
US20150259324A1 (en)	2015-09-17
CN106957282A (en)	2017-07-18
EA201691837A1 (en)	2017-12-29
PH12014501314A1 (en)	2014-09-15
JP2015506927A (en)	2015-03-05
BR112014015197A8 (en)	2017-06-13
US20170334882A1 (en)	2017-11-23
KR20170010109A (en)	2017-01-25
TWI622578B (en)	2018-05-01
BR112014015197A2 (en)	2017-06-13
DK2794565T3 (en)	2017-11-13
SG11201402660YA (en)	2014-10-30
US20150152073A1 (en)	2015-06-04
AU2012358332B2 (en)	2016-06-23
US9061008B2 (en)	2015-06-23
AU2012358332A1 (en)	2014-07-17
EP2794565A1 (en)	2014-10-29
JP2016222693A (en)	2016-12-28
MX359634B (en)	2018-10-03
US20140179665A1 (en)	2014-06-26
MX2014007261A (en)	2015-03-06
US9676747B2 (en)	2017-06-13
CO7051027A2 (en)	2014-09-10
US8629274B2 (en)	2014-01-14
JP2018172399A (en)	2018-11-08
JP6553551B2 (en)	2019-07-31
EP2794565B1 (en)	2017-07-26
EP3312160A1 (en)	2018-04-25
ES2649410T3 (en)	2018-01-11
KR101939710B1 (en)	2019-01-17
EP2794565A4 (en)	2015-06-24

Publication	Publication Date	Title
IL233182A0 (en)	2014-08-03	Hepatitis b antiviral agents
IL252345A0 (en)	2017-07-31	Antiviral compounds
IL258007A (en)	2018-06-28	Novel antiviral agents against hbv infection
IL239496A0 (en)	2015-08-31	Antiviral compounds
IL238785A0 (en)	2015-06-30	Antiviral azasugar-containing nucleosides
BR112014007781A2 (en)	2017-04-11	antiviral compounds
SG10201703451RA (en)	2017-06-29	Antiviral compounds
GB2505291B (en)	2015-08-12	Printed article
GB2491713B (en)	2016-08-03	Stroller
IL231132A0 (en)	2014-03-31	Viral clearnce methods
SI2525128T1 (en)	2014-04-30	Transition piece
BR112014007599A2 (en)	2017-04-11	antiviral compounds
EP2699241A4 (en)	2014-08-20	Antiviral compounds
EP2664621A4 (en)	2014-11-26	Antiviral agent
EP2691106A4 (en)	2014-12-24	Antiviral composition
GB2490711B (en)	2015-11-18	Wheel-supporting arrangement
GB201119531D0 (en)	2011-12-21	Aerofoils
EP2782585A4 (en)	2015-08-05	Antiviral formulations
GB201222939D0 (en)	2013-01-30	New Antiviral Compound 2
ZA201306909B (en)	2017-04-26	Antiviral composition
GB201121309D0 (en)	2012-01-25	Antiviral
ZA201402374B (en)	2015-11-25	Antiviral compounds
GB201105133D0 (en)	2011-05-11	Wheelbarrow
GB201118295D0 (en)	2011-12-07	Cross back bib
GB201117947D0 (en)	2011-11-30	Wheelbarrows

Movatterモバイル変換

SG10201608528YA - Hepatitis b antiviral agents - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=48669530

Family Applications (2)

Family Applications Before (1)

Country Status (21)

Families Citing this family (251)

Family Cites Families (247)

Also Published As

Similar Documents